Invivo Therapeutics (NVIV) Releases Earnings Results, Beats Expectations By $0.03 EPS

Invivo Therapeutics (NASDAQ:NVIV) issued its earnings results on Monday. The biotechnology company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03, Bloomberg Earnings reports.

Shares of Invivo Therapeutics (NVIV) opened at $0.67 on Tuesday. Invivo Therapeutics has a one year low of $0.45 and a one year high of $4.40. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $24.67, a PE ratio of -0.79 and a beta of 2.69.

TRADEMARK VIOLATION NOTICE: “Invivo Therapeutics (NVIV) Releases Earnings Results, Beats Expectations By $0.03 EPS” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at

About Invivo Therapeutics

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.

Earnings History for Invivo Therapeutics (NASDAQ:NVIV)

Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply